HLX02, a China-manufactured trastuzumab biosimilar versus EU-sourced trastuzumab: Results of a global phase 3, randomized, double-blind efficacy and safety comparative study in metastatic breast cancer-MedSci.cn

HLX02, a China-manufactured trastuzumab biosimilar versus EU-sourced trastuzumab: Results of a global phase 3, randomized, double-blind efficacy and safety comparative study in metastatic breast cancer

Xu, B; Zhang, Q; Sun, T; Li, W; Teng, Y; Hu, X; Bondarenko, I; Adamchuk, H; Li, Y; Shan, B; Cheng, J; Wang, X; Chen, Y; Jiang, W; Liu, S; Zhang, X; Liu, E; Luk, A; Wang, Q; Chai, K

EUROPEAN JOURNAL OF CANCER, 2020; 138 (): S68

科室
- - 订阅+
  - 更多科室
工具
服务